CareDx broadens HeartCare availability
“The marriage of gene expression profiling and dd-cfDNA promises additional insights as we continuously strive to improve the long-term care of our heart transplant patients,” says
“HeartCare provides a comprehensive view into the health of the heart allograft, so we are seeing strong initial interest from transplant cardiologists to join SHORE,” said
HeartCare establishes a standardized routine surveillance schedule for heart transplant patients, and is broadly available today to centers across
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts, including statements regarding HeartCare and its potential benefits. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the
Chief Commercial Officer
Integrated Corporate Relations, Inc.
Source: CareDx, Inc.